Indeed, enhancing anticancer immune responses by blocking the immunosuppressive molecules (i.e., IL-10, TGF-β, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed death 1 (PD-1), and PD-L1) expressed by cancer cells and tumor-infiltrating immune cells seems to be a promising therapeutic strategy in different types of cancers. Here, TGFB1 is linked to cancer.